[go: up one dir, main page]

TR199501327A3 - - Google Patents

Info

Publication number
TR199501327A3
TR199501327A3 TR95/01327A TR9501327A TR199501327A3 TR 199501327 A3 TR199501327 A3 TR 199501327A3 TR 95/01327 A TR95/01327 A TR 95/01327A TR 9501327 A TR9501327 A TR 9501327A TR 199501327 A3 TR199501327 A3 TR 199501327A3
Authority
TR
Turkey
Prior art keywords
halogen
alkyl
optionally substituted
group
bond
Prior art date
Application number
TR95/01327A
Other languages
Turkish (tr)
Other versions
TR199501327A2 (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of TR199501327A3 publication Critical patent/TR199501327A3/tr
Publication of TR199501327A2 publication Critical patent/TR199501327A2/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J19/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 by a lactone ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J21/00Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005Ketals
    • C07J21/006Ketals at position 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051Estrane derivatives
    • C07J1/0081Substituted in position 17 alfa and 17 beta
    • C07J1/0088Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0092Alkenyl derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J17/00Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J21/00Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/001Lactones
    • C07J21/003Lactones at position 17
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016Oximes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J51/00Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A steroid with a 17-spiromethylene lactone group having formula I <CHEM> wherein R1 is O, (H,H), (H,OR), or NOR, R being selected from H, (1-6C) alkyl and (1-6C) acyl; R2 is H, (1-6C) alkyl optionally substituted by a halogen, (2-6C) alkenyl optionally substituted by a halogen, (2-6C) alkynyl optionally substituted by a halogen, or halogen; R2' is H; or R2' together with R2 is a (1-6C) alkylidene group or a (2-6C) alkenylidene group; or R2' together with R3 is a bond; R3 is H if not together with R2' a bond; R4 is (1-6C) alkyl; one of R5 and R6 is hydrogen and the other is hydrogen or (1-6C) alkyl; X is (CH2)n or (CnH2n-2) wherein n is 2 or 3, which is optionally substituted with hydroxy, halogen, (1-6C) alkyl, (1-6C) acyl, (7-9C) phenylalkyl, the phenyl group of which may be substituted with (1-6C) alkyl, (1-6C) alkoxy, hydroxy or halogen; Y is O or (H,OH); and the dotted lines indicate optional bonds, at least one of bonds 4-5, 5-10, and 9-10 being a double bond. The steroids of the invention have progestational activity and can be used as contraceptives.
TR95/01327A 1994-10-27 1995-10-27 Steroids with 17-spiromethylene lactone or lactol group TR199501327A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP94203117 1994-10-27

Publications (2)

Publication Number Publication Date
TR199501327A3 true TR199501327A3 (en) 1996-06-21
TR199501327A2 TR199501327A2 (en) 1996-06-21

Family

ID=8217314

Family Applications (1)

Application Number Title Priority Date Filing Date
TR95/01327A TR199501327A2 (en) 1994-10-27 1995-10-27 Steroids with 17-spiromethylene lactone or lactol group

Country Status (26)

Country Link
US (1) US5741786A (en)
EP (1) EP0709394B1 (en)
JP (1) JPH08225590A (en)
KR (1) KR100402636B1 (en)
CN (1) CN1052237C (en)
AT (1) ATE199015T1 (en)
AU (1) AU689642B2 (en)
BR (1) BR9504576A (en)
CA (1) CA2161490A1 (en)
CZ (1) CZ287346B6 (en)
DE (1) DE69520022T2 (en)
DK (1) DK0709394T3 (en)
ES (1) ES2157290T3 (en)
FI (1) FI113542B (en)
GR (1) GR3035713T3 (en)
HU (1) HU221192B1 (en)
IL (1) IL115659A (en)
NO (1) NO305252B1 (en)
NZ (1) NZ280325A (en)
PL (1) PL187083B1 (en)
PT (1) PT709394E (en)
RU (1) RU2168516C2 (en)
SG (1) SG33569A1 (en)
TR (1) TR199501327A2 (en)
TW (1) TW339337B (en)
ZA (1) ZA958963B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407082B1 (en) * 1996-09-13 2002-06-18 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a vitamin D compound
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
DE19651000A1 (en) * 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
ATE473759T1 (en) 1998-05-22 2010-07-15 Univ Leland Stanford Junior BIFUNCTIONAL MOLECULES AND THERAPIES BASED THERAPIES.
US6043235A (en) * 1999-07-21 2000-03-28 Research Triangle Institute 11β-aryl-17, 17-spirothiolane-substituted steroids
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
JP4202250B2 (en) 2001-07-25 2008-12-24 バイオマリン ファーマシューティカル インコーポレイテッド Compositions and methods for modulating blood brain barrier transport
EP3827747A1 (en) 2005-04-28 2021-06-02 Otsuka Pharmaceutical Co., Ltd. Pharma-informatics system
US9062126B2 (en) 2005-09-16 2015-06-23 Raptor Pharmaceuticals Inc. Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof
DK3395372T3 (en) 2009-02-20 2022-04-19 Enhanx Biopharm Inc Glutathione-based drug delivery system
CN110075069A (en) 2009-05-06 2019-08-02 实验室护肤股份有限公司 Include activating agent-calcium phosphate granules compound dermal delivery composition and its application
CA3174401A1 (en) * 2020-04-03 2021-10-07 Daan De Kubber Method of draining water

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2875199A (en) * 1958-04-22 1959-02-24 Searle & Co Lactones of 17-carboxyalkylated estra-1, 3, 5(10)-triene-3, 17-diols and 3-ethers
US3547912A (en) * 1968-07-29 1970-12-15 American Home Prod Derivatives of 2h-pyran-3(6h)-ones and preparation thereof
US3764596A (en) * 1971-06-22 1973-10-09 Sandoz Ag 17-dihydrofuranyl-substituted steroids
DE3306554A1 (en) * 1983-02-22 1984-08-23 Schering AG, 1000 Berlin und 4709 Bergkamen METHOD FOR PRODUCING 3 - ((DELTA) (UP ARROW) 4 (UP ARROW) -3-KETOSTEROID-17 (ALPHA) -YL) -PROPIONSAEURELACTONES
DE3347510A1 (en) * 1983-12-27 1985-08-01 Schering AG, 1000 Berlin und 4709 Bergkamen Process for the preparation of 3-oxo-17 alpha -pregna-4,6-diene-21,17-carbolactones
FR2596395B1 (en) * 1986-03-26 1989-05-26 Roussel Uclaf NOVEL STEROIDS COMPRISING A SPIRANIC CYCLE IN POSITION 17, THEIR PREPARATION METHOD, THEIR APPLICATION AS MEDICAMENTS AND THE COMPOSITIONS CONTAINING THEM
ATE85342T1 (en) * 1987-12-12 1993-02-15 Akzo Nv 11-ARYLSTEROID DERIVATIVES.
FR2688004A1 (en) * 1992-02-27 1993-09-03 Roussel Uclaf NOVEL STEROUIDS COMPRISING IN POSITION 17 A RADICAL METHYLENE LACTONE, THEIR PROCESS AND PREPARATION INTERMEDIATES, THEIR APPLICATION AS MEDICAMENTS.

Also Published As

Publication number Publication date
RU2168516C2 (en) 2001-06-10
CN1052237C (en) 2000-05-10
IL115659A (en) 2000-06-01
HU221192B1 (en) 2002-08-28
JPH08225590A (en) 1996-09-03
GR3035713T3 (en) 2001-07-31
IL115659A0 (en) 1996-01-19
PT709394E (en) 2001-06-29
AU3445795A (en) 1996-05-09
NO954293L (en) 1996-04-29
ZA958963B (en) 1996-05-23
US5741786A (en) 1998-04-21
BR9504576A (en) 1997-05-20
TW339337B (en) 1998-09-01
KR100402636B1 (en) 2004-02-05
ES2157290T3 (en) 2001-08-16
FI113542B (en) 2004-05-14
PL311135A1 (en) 1996-04-29
DE69520022T2 (en) 2001-06-13
DK0709394T3 (en) 2001-06-18
PL187083B1 (en) 2004-05-31
ATE199015T1 (en) 2001-02-15
EP0709394A2 (en) 1996-05-01
FI955108A0 (en) 1995-10-26
KR960014152A (en) 1996-05-22
HUT73482A (en) 1996-08-28
CZ287346B6 (en) 2000-10-11
EP0709394B1 (en) 2001-01-31
FI955108L (en) 1996-04-28
DE69520022D1 (en) 2001-03-08
CZ275595A3 (en) 1996-05-15
NO305252B1 (en) 1999-04-26
HU9503068D0 (en) 1995-12-28
CN1131158A (en) 1996-09-18
CA2161490A1 (en) 1996-04-28
AU689642B2 (en) 1998-04-02
SG33569A1 (en) 1996-10-18
NO954293D0 (en) 1995-10-26
NZ280325A (en) 1997-03-24
EP0709394A3 (en) 1996-09-18
TR199501327A2 (en) 1996-06-21

Similar Documents

Publication Publication Date Title
TR199501327A3 (en)
AU3009392A (en) 17-spirofuran-3&#39;-ylidene steroids
CA2152819A1 (en) New antiparasitic agents related to the milbemycins and avermectins
EP0893446A4 (en)
IL112021A0 (en) Pharmaceutical compositions containing 1,2,3,4,4a,5,10,10a-octahydro-benzo-[g] quinoline derivatives for the prevention or delay of progressive atrophy of the optic nerve
YU49025B (en) New 17,20-epoxy pregnane drivatives, their use in the preparation of cortisone derivatives and intermediates therefor
ES2181372T3 (en) DERIVATIVES OF DIHYDRO- OR TETRAHYDRONAFTALENE THAT HAVE ACTIVITY (ANTI) -STROGENA.
IL117497A (en) 17-difluoromethylene estratriene derivatives and pharmaceutical compositions containing the same
ATE42957T1 (en) AQUEOUS CRYSTAL SUSPENSION OF STEROID GLYCOESTERS.
IE861677L (en) 11-methylene-15-ene steroids
NZ218918A (en) 4-oxo-1,4-dihydro-quinoline 3-carboxamides,their preparation and pharmaceutical compositions containing them
DK164873C (en) 3-KETO-17ALFA-MERCAPTO-17BETA (SUBSTITUTED THIO) -DROSTENDER DERIVATIVES USED AS INTERMEDIATES IN THE PREPARATION OF 17,17-BIS (SUBSTITUTED THIO) -3-KETOSTROSTERS PROMOTED.
DE69305659D1 (en) 17-phenyl substituted steroids with cardiotonic activity